Market Research Blog – Page 1462 – New Product Development

Automatic Filling Machine Market Analysis: Anticipated Growth at 4.8% CAGR from 2023 to 2033, Totaling US$ 8.88 Billion

The automatic filling machine Market report, unveiled by Future Market Insights—an ESOMAR Certified Market Research and Consulting Firm—presents invaluable insights and meticulous analysis of the automatic filling machine market. Encompassing the research’s scope and essence, this report scrupulously examines the driving factors, market size, and predictive data for automatic filling machine. It furnishes intricate revenue and shipment segmentations, accompanied by a decade-long projection up to 2033. Additionally, the document evaluates key industry players, their market distribution, the competitive scenario, and regional perspectives

The global automatic filling machine sector is forecasted to experience substantial expansion, with a projected average Compound Annual Growth Rate (CAGR) of 4.8% from 2023 to 2033. By 2033, it is expected that the market will command a considerable market share, estimated at US$ 8.88 billion, commencing its trajectory with a market valuation of US$ 5.56 billion in 2023.

Unveiling Dynamics of Demand and Challenges

Amidst a landscape of promising growth, the automatic filling machine market is fueled by a constellation of factors. Future Market Insights (FMI) sheds light on the driving forces behind the market’s ascent while delving into challenges identified during comprehensive analysis, offering profound insights into this dynamic market segment.

Delve into the Market Landscape Strategically: Unearth Profitable Growth Opportunities through Our Comprehensive Market Overview – Request Our Sample Now

Driving Forces Propelling the Market

Surge in FMCG and Pharma Demand: The escalating demand for fast-moving consumer goods (FMCG) and pharmaceutical products has spurred manufacturers to enhance production speed. Consequently, the need for automatic filling machines that can swiftly and accurately fill containers while maintaining volume and weight precision has intensified.

Consumer Quest for Efficiency and Hygiene: The embrace of aseptic packaging gains momentum as consumers seek healthy and sterile products. Manufacturers are investing in aseptic filling machines to cater to this heightened demand for product integrity and consumer safety.

Elevating Convenience and Automation: The global penchant for convenient food packaging has driven the trend of miniaturized packing. Leveraging production line automation, packaging solution providers are harnessing innovation and efficiency to achieve consistency, thereby propelling the growth of the automatic filling machine market.

Critical Restraints to Navigate

High Cost Barrier: The proliferation of programmable logic controllers, software integration, and feedback systems has led to a higher cost associated with automatic filling machines. This cost factor could potentially hinder market expansion.

Challenges in Aseptic Filling: Certain segments of the food and beverages industry necessitate aseptic filling machines, which tend to be more expensive than other variants available in the market.

North America’s Dominance and Dynamics

Forecasts suggest that the North American region is primed to command a significant share of the global automatic filling machine market. Presently, North America accounts for 25% of the total market share, with the United States alone capturing 20.7% in 2022. The region’s burgeoning pharmaceutical sector fuels the demand for automatic filling machines, catering to filling requirements of liquid medicine bottles, vials, capsules, and ampules.

Competitive Landscape: Innovating for Future Excellence

The allure of automatic filling machines has ignited a wave of innovation within the filling machines market. With productivity and process enhancement as focal points, industry players are exploring mergers, acquisitions, and strategic initiatives to foster market growth.

Strategy 1: Global Expansion for Technological Excellence

Manufacturers are strategically expanding their footprint in key countries of the Asia Pacific, a thriving hub of opportunities. Germany, renowned for technological advancement and quality packaging solutions, serves as a vital player. Collaborations and partnerships are being forged to extend high-quality filling solutions to end users in the Asia Pacific region.

As the automatic filling machine market surges forward, Future Market Insights continues to provide comprehensive insights and analyses, aiding stakeholders in navigating this evolving landscape.

Key Players

Accutek Packaging Equipment Companies, Inc.
Coesia S.p.A
GEA Group Aktiengesellschaft
JBT
Krones AG
Ronchi Mario S.p.A
Salzgitter AG (KHS Group)
Scholle IPN
Syntegon Technology GmbH
Tetra Laval International S.A.

For a Seamless Purchase Experience, Contact our Sales Team for Assistance

Key Segments Covered

By Sales Type:

New Machinery
Spare Parts

By Product Type:

Solid
Semi-solid
Liquid

By End-user Industry:

Food
Beverage
Pharmaceutical
Personal Care
Chemical
Others

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
LinkedIn| Twitter| Blogs | YouTube
For Sales Enquiries: sales@futuremarketinsights.com

Global Automatic Ducting Machine Market Projected to Reach US$ 2.2 Billion with a 4.3% CAGR by 2033

With a predicted CAGR of 4.3%, the automatic ducting machines market is expected to grow from a value of US$ 1.5 Billion in 2023 to US$ 2.2 Billion in 2033.The market for automatic ducting machines is expanding in part because to demand from the chemical processing and utilities/power industries. The market for automatic ducting machines experienced a CAGR of 3.6% over the historical period from 2016 to 2021.

Any form of industrial engine loses thermal efficiency while using wet steam, which can also cause a hydraulic lock or corrode internal parts. Automatic ducting devices are thus a requirement in many industrial operations where handling steam and moisture is inevitable. There are simpler variations of the standard steam separator, which uses a tangential intake and cyclonic motion to immediately separate steam and condensate.

Request A Sample PDF

Automatic ducting machines are available in a wide variety of sizes, pressure ranges, and applications. The expansion of the end use industries is directly correlated with the demand for automatic ducting machines. Over the forecast period, the global market for automatic ducting machines is anticipated to grow with a moderate CAGR due to the generally increasing growth rates of end use industries.

2016-2021 Automatic Ducting Machines Demand Analysis vs. Forecast 2022-2032

According to a report from Future Market Insights, the market for automatic ducting machines is expected to grow at a CAGR of 4.1% between 2022 and 2032, reaching a total of US$ 2,322.9 Million in 2032. (FMI). Sales increased significantly between 2017 and 2021, with a 3.6% CAGR.

The rapid adoption of automatic ducting machines is largely due to the presence of end user industries like chemical processing, pharmaceuticals, and oil & gas. Because of the COVID-19 pandemic’s restrictions on activities in some workplaces, the demand for automatic ducting machines was impacted.

The need for energy derived from various energy sources is anticipated to cause an increase in demand for automatic ducting equipment in the upcoming years. Additionally, it’s anticipated that during the forecast period, automation, speed increases, and innovation will alter the dynamics of automatic ducting machines.

Market Competition

Eaton, Didion Separator, Colton Industries, Kelburn Separation Specialists, Cole Industries Inc., Spirax-Sarco Engineering plc, Forbes Marshall, Kadant Inc., Sesotec Gmbh, and Penn Separator Corporation are major market participants in the automatic ducting machine market.

Penn Separator Corporation, a key player in the automatic ducting machines market is focusing on offering different types of ducting machines for various end user industries.
Kelburn Separation Specialists, another key player in the automatic ducting machines market is focusing on offering gas separators that lowers heat transfer rates.

Customization Before Buying, Visit

Key Segments Profiled in the Automatic Ducting Machine Industry Survey

Automatic Ducting Machine by Material Type:

Cast Steel Automatic Ducting Machine
Stainless Steel Automatic Ducting Machine
Aluminum Automatic Ducting Machine
Bronze Automatic Ducting Machine

Automatic Ducting Machine by Structure Type:

Flanged Automatic Ducting Machine
Fabricated Automatic Ducting Machine
Flanged and Fabricated Automatic Ducting Machine
Other Automatic Ducting Machine Structure Types

Automatic Ducting Machine by End Use Industry:

Automatic Ducting Machine for Utilities/Power
Automatic Ducting Machine for Chemical Processing
Automatic Ducting Machine for Oil and Gas
Automatic Ducting Machine for Paper and Pulp
Automatic Ducting Machine for Pharmaceuticals

Automatic Ducting Machine by Region:

North America Automatic Ducting Machine Market
Latin America Automatic Ducting Machine Market
Europe Automatic Ducting Machine Market
East Asia Automatic Ducting Machine Market
South Asia & Oceania Automatic Ducting Machine Mark
Middle East & Africa Automatic Ducting Machine Market

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us :

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports

Automated Cell Culture Systems Market is projected to grow at an 8.4% CAGR and reach USD 20.87 Billion by 2030 | FMI Analysis

The landscape of scientific research is undergoing a significant transformation, with the Automated Cell Culture Systems Market taking center stage. The global market for these systems is experiencing explosive growth, projected to reach a staggering USD 20.87 billion by 2030. This represents a remarkable Compound Annual Growth Rate (CAGR) of 8.4%, up from a valuation of USD 10.91 billion in 2022.

High-throughput screening technology has turned out to be the need of the hour, especially with large number of biological/chemical compounds being tested to target a particular ailment. As such, leveraging automation and robotics for quick testing of biochemical or biological activities is bound to drive the automated cell culture systems market.

Besides, 3D cell cultures, which were cumbersome and costly earlier, have become feasible, owing to advent of spheroids. Also, they imitate tumors better due to hypoxic core and presence of nutrient gradient.

Researchers in the US and Germany have come up with a protocol to grow 3D cultures of generally used cancer cells to facilitate drug screenings. These factors will continue to put North America and Europe at the top pedestal in the automated cell culture systems market.

Download a Sample Copy of This Report!

Further, the requirement of cell lines for devising vaccines against COVID-19 infection will augur well for the automated cell culture market despite the pandemic-induced economic downturn.

Automated Cell Culture Systems Market Outlook & Key Findings

Automated cell culture systems market is expected to witness a CAGR of 8% through 2030
Growing applications of cell lines in drug discovery to be a key growth driver
Consumables hold more than 60% of market value owing to ever-increasing research in stem cells and oncology
North America to capture more than 40% of market value and is expected to witness a CAGR of 6% through 2030
Biotech companies to remain prominent end users throughout the forecast period

Key Takeaways from the Automated Cell Culture Systems Market

Consumables are expected to reach US$ 11 Bn by 2030
Academic institutes are expected to take greater interest in research related to cell culture over the forecast period due to increased government funding in developed countries
North America and Europe collectively accounted for more than 60% of market share in 2019
Infinite cell line cultures held close to 75% of market share in 2019

“Advancements in technology, coupled with large-scale applications in cell-based drug delivery and drug discovery, are projected to drive the global automated cell culture systems market” – says the FMI analyst.

Request a Customization As per your Requirements:

New Product Launches to Remain Key Strategic Focus of Market Players

Players in the automated cell culture systems market are focusing on new product launches to expand their global footprint and strengthen product portfolio.

For instance –

In Jun 2020, faCellitate announced launching “BIOFLOAT”, its very first product to improve 3D cell culture.
In Mar 2020, BioProcess International started implementing single-use miniature bioreactors for supporting intensified cell culture by using functional performance indicators for assessing small-scale model
Corning Incorporated, in Oct 2019, came up with Corning Elplasia Plates and Matrigel for organoid culture. It was an addition to its 3D cell culture portfolio
Ori Biotech has started developing an automated way of manufacturing cell and gene therapies
In May, 2020, Sartorius announced launch of the Incucyte SX5® for live-cell analysis, for live-cell analysis experiments

Automated Cell Culture Systems Market: Competitive Insights

The global automated cell culture systems market is set to expand its scope in the forecast period, stimulated by increasing drug discovery research and diverse applications of cell lines in research purposes. Furthermore, automated cell culture systems are used for experiments in drug discovery research and in cell banking process. In addition, cost effectiveness and rise in alternative methods for traditional cell culture production is augmenting the adoption of automated cell culture systems.

Key market players covered in the market include Thermo Fisher Scientific, Corning Incorporated, Merck KGaA, Lonza, Sartorius AG, Tecan Trading AG, Hamilton Medical AG., Biospherix and Promocell GmbH. Key players integrate their positions through acquisitions, mergers and new product launches.

Contact Sales for Further Assistance in Purchasing this Report

Want more insights?

The study provides compelling insights on automated cell culture systems market on basis of product type (automated cell culture storage equipment, automated cell culture vessels, bioreactors and consumables), cell culture type (finite cell line cultures, infinite cell line cultures), application (drug development, stem cell research, regenerative medicine and cancer research) and end user (biotech companies, research organizations, academic institutes), and across seven major regions.

Author by

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Oligonucleotide API Market is anticipated to grow at a strong 5.60% CAGR to reach USD 4.84 Billion By 2034 | FMI Analysis

The quest for groundbreaking treatments is driving rapid growth in the Oligonucleotide API Market. These specialized molecules are essential building blocks for developing new drug classes to combat a wide range of diseases. According to a recent analysis, the market is poised for significant expansion, with a projected Compound Annual Growth Rate (CAGR) of 5.60% from 2024 to 2034. This translates to a remarkable surge from a valuation of USD 2.81 billion in 2024 to a staggering USD 4.84 billion by 2034.

Based on an analysis by FMI, the current landscape reveals that over 100 oligonucleotide APIs are advancing through clinical trial phases with regulatory approval on the horizon. Post-approval, there is an anticipated surge in the demand for production capacity, thereby propelling the oligonucleotide API market’s growth trajectory through 2030.

Oligonucleotides are emerging as a prominent class of therapeutics, following in the footsteps of biologics and small molecules. This shift is attributed to their potential to develop drugs at reduced costs, making them a promising avenue for the pharmaceutical industry.

Click Here to Access More Insights on this Market, Get A Sample Report

Apart from immune therapy, microbial and cardiovascular infections, and cancer, oligonucleotide APIs are being tried out to treat neurological disorders like Alzheimer’s as well. However, factors like regulatory complexities and timely delivery of oligonucleotides (amidst COVID-19) are acting as restraints.

Key Takeaways from Oligonucleotide API Marker Study

Antisense oligonucleotide APIs are anticipated to reach US$ 4 Bn by 2030.
North America and Europe collectively accounted for more than 47% of revenue share in 2019 while Asia Pacific is expected to grow at the fastest rate in the forecast period.
Increase in the use of antisense oligonucleotide APIs (especially post-approval from the US FDA in 2016) to boost the market in the forecast period

“Inorganic mode of growth coupled with broad therapeutic applications in gene therapy is expected to bolster the oligonucleotide API market,” says the FMI analyst.

New Product Launches: Key Indicators to Oligonucleotide APIs Market

FMI has analyzed players such as Akcea Therapeutics, Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., and Dynavax Technologies in this report. According to the analysis, these players are consolidating their positions through new product launches.

For instance –

In March 2020, Dynavax entered into a collaboration with Clover Biopharmaceuticals to develop a vaccine candidate to combat COVID-19. Clover is into advanced evaluation of its Covid-19 S-Trimer, protein-based coronavirus vaccine candidate and Dynavax has its technical expertise along with proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018 for executing this.
Alnylam Pharmaceuticals, Inc., in 2018, launched Givlaari and Onpattro at the commercial level.

Gene Therapy and Oligonucleotide APIs

Synthetic oligonucleotides are being used in gene therapy for inactivating genes that help in propagating the disease. Antisense oligonucleotide APIs are used for disrupting the faulty gene’s transcription.

Also, siRNA could be used for signaling the cell to disrupt faulty mRNA’s translation. Along these lines, Pharmamar, in Jan 2020, signed an agreement with Jazz Pharmaceuticals to sell the API for “lurbinectedin”, one of the late-phase treatments for SCLC (small cell lung cancer) so that the latter could commercialize it.

Get Your Customized Impactful Report Now!

Key Segments of Oligonucleotide API Industry Survey:

by API:

Antisense Oligonucleotides APIs
Short Interfering RNA (siRNA) APIs
Phosphorodiamidate Morpholino Oligonucleotides (PMO) APIs
MiRNA APIs
Aptamers APIs
CpG Oligonucleotides APIs
Others (ON Conjugates (NP), ShRNA, etc.)

by Marketing Status:

Marketed
Clinical Trials (Clinical Phases)

by End User:

Contract Manufacturing Organizations (CMOs)
Pharmaceutical Companies
Biopharmaceutical Companies
Contract Development & Manufacturing Organizations (CDMOs)

by Region:

North America Oligonucleotide API Market
Latin America Oligonucleotide API Market
Europe Oligonucleotide API Market
East Asia Oligonucleotide API Market
South Asia & Pacific Oligonucleotide API Market
Middle East & Africa (MEA) Oligonucleotide API Market

Key Companies Profiled:

Jazz Pharmaceuticals, Inc.
Sarepta Therapeutics
Biogen
Dynavax Technologies
Akcea Therapeutics.
Alnylam Pharmaceuticals, Inc.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Eye Infection Treatment Market is projected to be worth USD 9.9 Billion, growing at a CAGR of 3.8% By 2030 | FMI

The importance of maintaining clear and healthy vision is driving growth in the Eye Infection Treatment Market. A recent analysis reveals that the market reached a value of USD 7.3 billion in 2022 and is poised for steady growth at a Compound Annual Growth Rate (CAGR) of 3.8% through 2030. This translates to a projected market value of a staggering USD 9.9 billion by 2030.

Rising Caseloads

Caseloads of ocular surgical conditions such as cataracts, glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy are growing due to sedentary lifestyle habits, and expanding geriatric cohort. According to the US statistics 2021, cataracts affect over 24 million Americans aging at least 40 years.

By age 75, about half of Americans suffer from cataracts. Further, diabetic retinopathy affects nearly 7.7 million Americans aging at least 40 years. Similarly, there were 48,229 corneal transplants performed in the US in 2015.

Demand for eye infection treatment will continue to receive a strong impetus from increasing awareness about different eye infection types and availability of treatment, further complemented by technological advancements on ophthalmology.

Download Sample PDF of this Report:

Key Takeaways of Eye Infection Treatment Market Study

Antibiotics would contribute over 55% of revenue share in the eye infection treatment market owing to their use in treating primary eye infections and post-surgical eye infections.
Eye drop sales capture over 60% market share in the eye infection treatment market.
Conjunctivitis would account for a third of eye infection treatment demand through 2030.
Bacterial infections continue to account for over 3/5^th market share.
Hospitals and retail pharmacies collectively generate over 70% total returns to shareholders.
Increasing rate of eye surgeries and rising usage of contact lenses continue to push North American market. European market would be upheld by the expanding geriatric pool.

Demand for Eye Infection Drugs to Slump Amidst COVID-19 Pandemic

The coronavirus (COVID-19) pandemic has resulted in widened gap between supply and demand of eye infection treatments. As such, it has significantly reduced ocular surgery rate for short-term basis and, in turn, post-operative eye infections.

According to World Health Organization (WHO), national healthcare resources redirection and utilization to contain COVID-19 pandemic is expected to delay and reschedule the treatment of non-critical healthcare conditions for brief period, including eye care services, and ocular surgeries.

Development and Licensing Deals with Multiple Commercialization Partners

Technology developers are laying greater emphasis on developing of novel ophthalmic formulation technologies and engaging with commercialization partners with licensing-out proprietary ophthalmic technologies.

For instance, Nicox S.A. has licensed out ZERVIATE (cetirizine ophthalmic solution) 0.24% to Eyevance Pharmaceuticals LLC for commercialization of ZERVIATE in the US. ZERVIATE is the first topical ocular formulation of antihistamine cetirizine approved for treatment of ocular itching associated with allergic conjunctivitis. In addition, Ocumension Therapeutics is responsible for all development and commercialization activities in the Chinese market for ZERVIATE.

Purchase the Report for Growth Analysis
Eye Infection Treatment Market Key Segments:

By Drug Class :

Antibiotics
- Sulfonamides
- Macrolides
- Erythromycin
- Chloramphenicol
- Aminoglycosides
- Fluoroquinolones
- Vancomycin
- Tetracyclines
Antivirals
- Thymidine-Based Nucleoside Analogues (Trifluridine)
- Thymidine Phosphorylase Inhibitors (Trifluridine)
- Acyclic Nucleoside Analogue of 2’Deoxyguanasine (Ganciclovir)
- Acyclic Guanine Nucleoside Analog (Acyclovir)
- Others
Antifungals
- Polyenes (Amphotericin B (AMB) And Natamycin (NTM))
- Azoles (Miconazole (MCZ), Econazole (ECZ) And Ketoconazole (KCZ))
- Pyrimidines
- Echinocandins (Caspofungin (CFG) and Micafungin (MFG))
- Others
Antihistamines
Corticosteroids
Glucocorticoids

By Dosage Form :

Eye Infections Treatment Tablets
Eye Infections Treatment Capsules
Eye Infections Treatment Ophthalmic Ointments
Eye Infections Treatment Eye Drops
Others

By Indication :

Eye Infections Treatment for Conjunctivitis
Eye Infections Treatment for Keratitis
Eye Infections Treatment for Endophthalmitis
Eye Infections Treatment for Blepharitis
Eye Infections Treatment for Stye or Sty (Hordeolum)
Eye Infections Treatment for Uveitis
Eye Infections Treatment for Cellulitis
Eye Infections Treatment for Ocular Herpes

By Causative Agent :

Virus
Bacteria
Fungus
Allergens

By Distribution Channels :

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Drug Stores

By Region :

North America Eye Infections Treatment Market
Latin America Eye Infections Treatment Market
Europe Eye Infections Treatment Market
East Asia Eye Infections Treatment Market
South Asia & Pacific Eye Infections Treatment Market
Middle East & Africa (MEA) Eye Infections Treatment Market

Author

Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Corneal Ulcer Treatment Market is expected to grow at a 5.7% CAGR and reach USD 1.27 Billion by 2029 | FMI Study

The global Corneal Ulcer Treatment Market is experiencing a surge, fueled by increased awareness and innovative treatments. According to a recent analysis by Future Market Insights (FMI), the market was valued at a substantial USD 867.3 million in 2022. Looking ahead, the market is projected to climb steadily at a Compound Annual Growth Rate (CAGR) of 5.7%, reaching an impressive USD 1.27 billion by 2029.

Corneal ulcers, a severe ocular condition with a global impact, significantly threaten vision health. The rising prevalence of corneal ulcers has ignited the development of advanced treatment options, driving the Global Corneal Ulcer Treatment Industry towards unprecedented growth.

“Low-cost drugs being offered by generic drug manufacturers, especially in emerging countries, has substantially lowered treatment cost, and is giving tough competition to key players in the Global Corneal Ulcer Treatment Industry.”

Request a Sample of this Report Now!

Key Takeaways of Corneal Ulcer Treatment Market Study

Treatment of broad-spectrum corneal ulcers using antibiotics is expected to gain traction and contribute more than 75% of revenue share during the forecast period.
Growing bacterial keratitis requiring antibiotics for treatment will contribute significantly to the segment’s revenue share.
Eye drops or eye ointments dominate the market by form type, as these are relatively cheaper and do not require another interventional and oral route for drug delivery.
By distribution channel, retail pharmacies are expected to gain more than 50% of the market share during the forecast period.
North America dominates the Global Corneal Ulcer Treatment Industry, while East Asia is expected to offer lucrative growth opportunities, owing to rising healthcare infrastructure and industrialization.

Acquisition – Key Strategy Followed by Leading Manufacturers

Leading manufacturers in the Global Corneal Ulcer Treatment Industry are focusing on geographical expansion as well as increased product offerings through partnerships and acquisitions. To evaluate cost-effective therapy for corneal ulcer treatment, manufacturers are evaluating new drugs via clinical trials For example, in Dec. 2019, Mallinckrodt plc enrolled the first patient in the company’s Phase 4, multi-center, multiple-dose, open-label study to assess the effects of Acthar Gel as a therapy option in patients with severe keratitis.

Access Exclusive Market Insights – Purchase Now!

Key Segments Covered In Corneal Ulcer Treatment Market Research

By Drug class:

Antibiotics
Antifungals
Antivirals
Corticosteroids
NSAID’s

By Form:

Tablet
Eye Drops/ Ointments
Vials

By Route of Administration:

Oral
Topical
Injectables

By Indication:

Bacterial Keratitis
Fungal Keratitis
Viral Keratitis

Author

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Sleep Apnea Implants Market is anticipated to grow at a 13.8% CAGR and reach USD 1.2 Billion by 2033 | FMI Analysis

Millions around the world grapple with sleep apnea, a sleep disorder that disrupts rest and impacts overall health. Fortunately, a ray of hope is emerging from the Sleep Apnea Implants Market. This market is experiencing significant growth, offering a promising solution for those affected by this debilitating condition.

Currently valued at USD 317.1 million in 2023, the market is projected to reach a staggering USD 1,158.1 million by 2033. This translates to a robust Compound Annual Growth Rate (CAGR) of 13.8%, highlighting a growing acceptance and adoption of these innovative implants.

One of the pivotal opportunities within this burgeoning landscape is the advancement of minimally invasive implant procedures. In this era of innovation, manufacturers have honed their focus on crafting implants that offer ease of insertion and adjustment with minimal surgical intervention. This strategic shift not only mitigates patient discomfort but also substantially reduces recovery times, leading to cost savings within the healthcare sector.

An exciting development in the realm of Sleep Apnea Implants is the integration of Artificial Intelligence (AI) and Machine Learning (ML) algorithms. By harnessing the power of these cutting-edge technologies, implants can now continuously monitor and analyze sleep patterns. They can adapt therapy settings in real time, ultimately offering personalized treatment solutions that are tailor-made for individual patients.

Request a Sample Copy of This Report Now.

There is a growing demand for implantable devices that offer multi-modal therapy options. Key players are exploring the combination of neurostimulation with other therapeutic modalities, such as drug delivery or positional therapy, to provide comprehensive and more effective treatment solutions.

Advancements in remote monitoring and telemedicine technologies are creating opportunities for improved patient care and enhanced follow-up. Implants with remote monitoring capabilities enable healthcare providers to monitor therapy effectiveness, make necessary adjustments remotely, and provide timely interventions when needed.

Key Takeaways from the Sleep Apnea Implants Market:

According to FMI, the United States is leading the growth in North America, capturing approximately 84.1% of the market share in 2022.
Sales of Sleep Apnea Implants in India are projected to experience a significant surge with an estimated compound annual growth rate (CAGR) of 18.2% in 2022.
The market for Sleep Apnea Implants will be predominantly driven by the OSA segment, which will continue to grow and dominate the market throughout the forecast period.
Hypoglossal Neurostimulation Devices hold the largest market share of 84.66% in the Global Sleep Apnea Implants Industry, indicating their prominence in the industry.
The OSA segment is expected to maintain its dominance in the Global Sleep Apnea Implants Industry, accounting for a market share of 91.34%.

“The Sleep Apnea Implants market represents a promising horizon for individuals affected by sleep apnea, as groundbreaking technologies are revolutionizing their lives by bringing back restful nights and rejuvenating their overall well-being during the day”, remarks an analyst at FMI.

How Key Players are Revolutionizing the Manufacturing of the Sleep Apnea Implants Market?

Key players in the Sleep Apnea Implants market are driving a revolution in manufacturing by introducing advanced technologies and innovative approaches. These companies are leveraging their expertise to develop implantable devices that provide effective and personalized treatment options for patients with sleep apnea.

By integrating cutting-edge features such as neurostimulation, these implants target the root cause of the condition and regulate breathing patterns during sleep. Key players are also focusing on improving patient experience by developing user-friendly therapy management systems that allow for remote monitoring and customization. With their continuous efforts, these manufacturers are revolutionizing the manufacturing of Sleep Apnea Implants, offering enhanced treatment outcomes and improving the quality of life for patients.

Key Players in the Sleep Apnea Implants Market:

Inspire Medical Systems
Respicardia, Inc.
Medtronic Plc
LinguaFlex LLC
Siesta Medical, Inc.
Pillar Palatal LLC / The Snoring Center
Nyxoah SA
LivaNova/ImThera

Product Portfolio:

Inspire Medical Systems offers a comprehensive product portfolio in the field of sleep apnea treatment. Their innovative solutions include implantable devices and therapy management systems that provide effective and personalized treatment options for patients suffering from sleep-related breathing disorders.
Respicardia, Inc. specializes in providing a diverse product portfolio for the treatment of central sleep apnea. Their offerings include implantable neurostimulation devices that help regulate breathing and improve sleep quality, offering patients advanced and tailored solutions for managing their respiratory conditions.

Access Exclusive Market Insights – Purchase Now!

More Insights Available:

Future Market Insights offers an unbiased analysis of the Global Sleep Apnea Implants Industry, providing historical data from 2018 to 2022 and forecast statistics from 2023 to 2033.

Sleep Apnea Implants Market Segmentation:

By Product:

Phrenic Nerve Stimulator
Hypoglossal Neurostimulation Devices
Bone Screw Implant System
Flexible Tongue Retractor System
Palatal Implants/Pillar Procedure

By Indication:

Central Sleep Apnea
Obstructive Sleep Apnea (OSA)

By End User:

Hospitals
Ambulatory Surgical Centers
Office Based Clinics

Author

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Lacrimal Devices Market is expected to reach USD 39.7 Million by 2029, expanding at a 5.5% CAGR | FMI Analysis

The global Lacrimal Devices Market is experiencing steady growth, according to a recent analysis by Future Market Insights (FMI). The market is projected to reach a value of USD 39.7 million by the end of 2029, reflecting a significant rise from its approximate valuation of USD 25.6 million in 2021. This growth is attributed to a Compound Annual Growth Rate (CAGR) of 5.5%.

Lacrimal devices, notably Nasolacrimal stents, have emerged as a groundbreaking advancement in ophthalmic care. These devices provide a novel solution for tear drainage in cases where traditional tear ducts are nonfunctional, and alternative drainage options are limited. The inception of lacrimal stents dates back to 1932 when Dr. Graue introduced the concept, of utilizing silver wire as the primary material.

Request a Sample Copy of This Report Now.

Over the years, the lacrimal devices landscape has witnessed significant advancements, with various materials like silk, nylon, polyethylene, and polypropylene being employed to enhance performance and patient comfort. These small tubes are typically constructed from silicone or other semi-rigid yet flexible materials, featuring an open center lumen for optimal tear drainage.

The Global Lacrimal Devices Industry’s impressive growth can be attributed to ongoing innovations and increasing demand for effective tear drainage solutions. With a 5.5% CAGR driving the market’s expansion, it is clear that lacrimal devices are becoming an integral part of the ophthalmic industry, offering hope and improved quality of life to countless individuals worldwide.

The increased demand for ophthalmic treatments with greater success rates and minimum intrusions, as well as an increase in patients with nasolacrimal duct obstruction, are driving the Global Lacrimal Devices Industry.

During the projected period, the introduction of innovative and high-success-rate treatments will move the market forward. The adoption of precise and updated lacrimal devices, such as the new lacrimal cannula, which combines flexibility and strength to prevent trauma by providing easy access to the canaliculus, is a fundamental driver of market expansion.

Get Your Customized Impactful Report Now!

Manufacturers Emphasizing Advanced Product Development

Numerous organizations are focusing on new product development for lacrimal duct stent tubes. In June 2019, FCI Ophthalmic offered a complete line of BIKA stents namely, BIKA, BIKA for DCR, and Infant BIKA covering a range of sizes that will benefit most of the congenital nasolacrimal duct obstruction (CNLDO) and dacryocystorhinostomy (DCR) cases.

Key Takeaways – Lacrimal Devices Market Study

Bicanalicular lacrimal duct stent tube is expected to contribute a fourth of the revenue share in the lacrimal duct stent tube market owing to its high success rate in stent placement.
Hospitals captured the maximum share of the lacrimal duct stent tube market owing to the highest patient footfall followed by ophthalmic clinics.
Attributed to the growing patient pool for retinal diseases, especially due to premature births, contributed to the dominance of North America in the lacrimal duct stent tube market.
Increasing awareness for the availability of the treatment for nasolacrimal duct stent obstruction among caregivers of prematurely born babies and an increasing number of skilled professionals are expected to drive the growth of the lacrimal duct stent tube market in East Asia.

Lacrimal Devices Market Competitive Landscape

FCI Ophthalmics
Kaneka Corporation (Kaneka Pharma America LLC)
Gunther Weiss Scientific Glass
Bess Medizintechnik GmBH

Purchase The Full Report Now!

Key Segments Covered In Lacrimal Devices Market Research

By Product:

Monocanalicular Lacrimal Duct Stent Tube
Bicanalicular Lacrimal Duct Stent Tube

By End User:

Hospitals
Ophthalmic Clinics
Ambulatory Surgical Centers

Author

Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Radiation Toxicity Treatment Market is anticipated to expand at a CAGR of 5.8% by 2029, reaching USD 5.58 Billion | FMI Study

The fight against cancer involves powerful treatments, but these can sometimes come with challenging side effects. The Radiation Toxicity Treatment Market is on the rise, reflecting the growing need for effective solutions to manage these side effects. According to a recent industry report by Future Market Insights (FMI), the global market for Radiation Toxicity Treatment was valued at USD 3.76 billion in 2022. This market is poised for significant growth, projected to reach a staggering USD 5.58 billion by 2029.

The installed base of internal radiation therapy machines has increased considerably over the previous decade. Improving reimbursement situations and a favorable government policy framework in the field of cancer treatment are expanding radiation therapy accessibility, which is positively impacting the Radiation Toxicity Treatment market.

Get a PDF Sample with the Latest Market Insights

According to the report, big corporations in the Asia Pacific will continue to invest heavily in the development of novel radiation therapies in response to the region’s increased cancer prevalence and improved rate of detection.

The increasing prevalence of radiation poisoning in the healthcare and chemical industries necessitates the development of effective therapies. Another important factor driving the market growth is the recent FDA clearance of many orphan drugs that have been found to significantly improve survival rates in adult and pediatric radiation sickness patients. These application areas continue to offer potential opportunities in the Radiation Toxicity Treatment market.

Key Takeaways – Radiation Toxicity Treatment Market Study

By 2029, the increased usage of colony-boosting medicines, such as Amgen’s Neulasta, will account for more than 75% of revenue in the Radiation Toxicity Treatment market.
Because of the high incidences of radiation toxicity caused by gamma radiation emission from positron emission tomography (PET) and single-photon emission computed tomography (SPECT) scanners installed in hospitals and diagnostic centers, non-ionizing radiation is expected to provide a lucrative opportunity for market participants.
North America remains the market leader in Radiation Toxicity Treatment, but South Asia is predicted to grow fast shortly.

Who Is Winning?

Some of the key players operating in the Radiation Toxicity Treatment market include Amgen Inc., Partner Therapeutics, Mylan N.V., and Novartis AG. Leading players of the Radiation Toxicity Treatment market are focusing on acquiring smaller companies to enhance their product portfolio and improve regional market positioning.

For instance, Siegfried Group announced the acquisition of drug product manufacturing facility together with all related employees and contracts from Arena Pharmaceuticals GmbH in Zofingen, Switzerland. Also, in 2018, Partner Therapeutics (PTx) acquired global rights to develop, manufacture, and commercialize Leukine (sargramostim) from Sanofi.

More insights available

North America is expected to dominate the radiation toxicity market due to the high incidence of cancer in the region, favorable reimbursement policies, and well-established healthcare infrastructure. Europe is also expected to witness significant growth in the radiation toxicity market due to increasing government initiatives to promote radiation therapy and rising investments in research and development activities.

Contact Sales for Further Assistance in Purchasing this Report

Radiation Toxicity Treatment Market by Category

By Product:

Colony Stimulating Factors
Potassium Iodide
Prussian Blue
Diethylenetriamine Pentaacetic Acid
Others

By Indication:

Acute Radiation Syndrome
- Bone Marrow Syndrome (Hematopoietic)
- Gastrointestinal Syndrome (GI)
- Cardiovascular (CV)
Chronic Radiation Syndrome

By Radiation Type:

Ionizing Radiation
- Alpha Radiation
- Beta Radiation
- Gamma Radiation
Non-ionizing Radiation

By End-User:

Hospitals
- Government Hospitals
- Private Hospitals
Research & Academic Institutes
- Government Research and Academic Institutes
- Private Research and Academic Institutes

Author

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Implantable Drug-Eluting Devices Market is Anticipated to Expand at a 6.0% CAGR and Reach USD 19.3 Billion by 2029 | FMI Research

The battle against chronic diseases is gaining a powerful ally: Implantable Drug-Eluting Devices Market. These innovative medical technologies are revolutionizing patient care by providing sustained drug delivery. According to a recent analysis by Future Market Insights (FMI), a leading market research firm, the global market for these devices is poised for significant growth, reaching a staggering USD 19.3 billion by 2029. This represents a robust Compound Annual Growth Rate (CAGR) of 6.0%, building on a strong foundation of approximately USD 12.8 billion in 2022.

In a noteworthy trend, manufacturers leading the industry are harnessing advancements in micro and nanotechnology to craft innovative implantable drug-eluting devices, steering the industry towards unprecedented growth. These cutting-edge devices exhibit controlled and site-specific attributes, along with compatibility for targeted drug delivery. This unique combination not only simplifies intricate dosing schedules but also mitigates the systemic toxicity associated with conventional drug delivery systems.

Request a Sample of this Report Now!

Remote-Controlled Chips and Programmable Devices – Future of Targeted Drug Delivery

Increasing clinical trials and research & development of remote-controlled and programmable drug-eluting devices Massachusetts Institute of Technology (MIT) researchers have developed a remote-controlled contraceptive hormone (levonorgestrel) delivery chip implant, which can turn the device on and off. Implantable drug-eluting devices allow minimum effective doses and support oral opioid weaning

Implantable drug-eluting devices such as SynchroMed II intrathecal drug delivery system with a controlled workflow system, play an effective role in reducing or eliminating the use of oral opioids. Antiretroviral (ARV) drug implant is expected to emerge as a promising approach for HIV treatment and prevention In July 2022, Merck & Co. started the development of slow-release antiretroviral (ARV) drug implants as a promising approach for HIV treatment.

The growth of the Global Implantable Drug Eluting Devices Industry can be prominently attributed to the associated cost-effective technology and novel medication administration techniques. Fewer side effects while these devices are utilized in the management of chronic diseases as well as in contraception have been the strongest attribute accounting for a steadily expanding market for implantable drug-eluting devices. Says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)

Know More About Implantable Drug-Eluting Devices Market Report

The Global Implantable Drug-Eluting Devices Industry, a new study from Future Market Insights, opines on the evolution of the implantable drug-eluting devices market from 2014 – 2021 and presents demand projections from 2022 – 2029 based on product type (implantable drug infusion pumps, intraocular drug-eluting devices, contraceptive drug-eluting devices, buprenorphine implant, and drug-eluting stents), technology (active drug-eluting devices and passive drug-eluting devices) applications (diabetes macular edema, birth control/contraception, opioid addiction, cardiovascular, ophthalmology, oncology, pain management, others) implantation type (intravaginal, intravascular, intraocular, intrathecal, subcutaneous, intrauterine) end users (hospitals, ambulatory surgical centers, optical care centers, cardiac surgery centers, office-based setting, and others) in seven prominent regions.

Medical-Pharma Collaborating to Balance Demand and Supply

A comprehensive view of the Global Implantable Drug Eluting Devices Industry has led our analysts to conclude that, the market is expected to grow at an impressive rate. This market growth is mainly attributed to increasing innovations and developments in implantable drug-eluting devices for the management and treatment of breast cancer, schizophrenia, Parkinson’s disease, and photosensitivity diseases. Besides, FMI analyst suggests that markets in North America and Europe are expected to hold major value shares in the global implantable drug-eluting devices landscape. Medical device companies are collaborating with pharmaceutical companies to develop efficient drug-delivery devices to cater to the rising demand for implantable drug-eluting devices.

Increasing use of syringe-based subcutaneous implantable drug-eluting devices is anticipated to minimize the number of invasive surgical procedures. The introduction of implantable drug-eluting devices or rare conditions such as central precocious puberty (CPP) will emerge as an important factor shaping the market for implantable drug-eluting devices.

Get Your Report on Discount Before It’s Gone!

Key Segments Covered in Implantable Drug-Eluting Devices Market Research

By Product:

Implantable Drug Infusion Pumps
Intraocular Drug-Eluting Devices
Contraceptive Drug-Eluting Devices
Buprenorphine Implant
Drug-Eluting Stents
Others

By Technology:

Active Drug Eluting Device
Passive Drug Eluting Device
- Biodegradable Implants
- Non-Biodegradable Implants

By Application:

Diabetic Macular Edema
Birth Control/Contraception
Opioid Addiction
Cardiovascular
Ophthalmology
Oncology
Pain Management

Author

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us: